Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. University of Minnesota, Minneapolis, MN, United States

Survival: 10.0 months
Toxicity Grade: 3
Treatments: Immunotherapy
Country: United States
City/State/Province: Minneapolis, MN
Hospital: University of Minnesota
Journal: Link
Date: 12/2012

This phase 2 study involved advanced melanoma patients who were divided into two separate treatment groups. There were 11 patients in group A and 10 patients in group B. Age and gender information was not provided.

Patients in group A were treated with the immunotherapy agent interleukin-2 (IL-2; stimulates the immune system) and the vaccine called allogeneic large multivalent immunogen (LMI) vaccine, which directs the immune system to target melanoma cells.

Patients in group B were treated with IL-2 alone.

The most severe toxicity in group A was grade 4 deep vein thrombosis (blood clot). Grade 3 nausea, weakness, back pain, and abdominal pain were also reported.

The most severe toxicities in group B were of grade 3 and included nausea, weakness, back pain, and abdominal pain.

The median overall survival for groups A and B was 11.9 and 10.0 months, respectively.

Correspondence: Dr. Arkadiusz Z. Dudek; email:

E-mail to a Friend Email Physician More Information